# Fruquintinib DDI Study With P-gp and BCRP Substrates

> **NCT05368805** · PHASE1 · COMPLETED · sponsor: **Hutchmed** · enrollment: 32 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib
- **DRUG:** Dabigatran Etexilate
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT05368805
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-02
- **Primary completion:** 2022-04-22
- **Final completion:** 2022-04-22
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05368805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05368805, "Fruquintinib DDI Study With P-gp and BCRP Substrates". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05368805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*